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distinguishable. When measured
by spectrophotometer, readings
for all samples were higher than
those for the 0 ng/L calibrator;
OOM extracts provided signals
that were well above those of the
400 ng/L calibrator.
In summary, simple aqueous
extracts from small portions of 6
different OOM-associated tumors
revealed very high FGF-23 concen-
trations as assessed by the calibra-
tor assay; FGF-23 concentrations
were also readily detectable by a
modified rapid test that takes30
min to complete. Like intraopera-
tive parathyroid hormone assays
(5 ), this rapid assay could be per-
formed in or near the operating
room, especially because visual in-
spection of the test plate was suffi-
cient to detect FGF-23 in all 6 tu-
mors tested. The assay may
furthermore help define, intraop-
eratively, the disease-free margins
of tumors located in areas that are
difficult to access surgically.
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More Studies on Outcomes
Using Biochemical Diagnostic
Tests Are Needed: Findings
from the Danish Society of
Clinical Biochemistry
To the Editor:
The results of biochemical tests of-
ten lead to diagnostic and thera-
peutic interventions, and the real
value of a test can be assessed only
by taking into account the subse-
quent health outcomes. The im-
portance of outcomes studies, and
the challenges in performing them,
was reviewed by Bruns in 2001 (1 ),
who argued that this type of study
should be performed more fre-
quently, and that such studies
should be used to determine
whether new tests should be imple-
mented in clinical practice.
To investigate the extent to
which this recommendation has
been realized, a working group on
evidence-based clinical biochemis-
try established by the Danish Soci-
ety of Clinical Biochemistry under-
took a pilot study to record the
number and type of reports of
diagnostic biochemical outcome
studies published from January
2005 to January 2006 in 4 medical
journals: Clinical Chemistry, Clini-
cal Chemistry and Laboratory Med-
icine, Lancet and the New England
Journal ofMedicine. To be included
as an outcome study, the reported
study had to be designed to inves-
tigate outcomes in relation to a
clinical or an economical variable
of a well-defined clinical applica-
tion of a biochemical test.
To identify reports of out-
come studies, 2 authors manually
went through reports published in
each of the journals within a 12-
month period. Detailed informa-
tion on original full-length reports
considered diagnostic biochemical
outcome studies was registered to-
gether with the total number of
original articles. Technical Briefs,
Letters, Short Communications,
Editorials, and Reviews were not
included. When there were dis-
crepancies in report selection by
the 2 authors scrutinizing the same
journal issues, a consensus deci-
sion was made in the entire author
group. Selected outcomes reports
were classified as investigating (A)
direct clinical mortality or morbid-
ity; (B) other clinical variables such
as length of hospital stay, readmis-
sion rate, or satisfaction with care;
or (C) economic outcomes.
A total of 829 original articles
were registered, of which only 7
studies (0.8%) were classified as
diagnostic biochemical outcome
studies (Table 1). Six (of 231) of
these original articles were pub-
lished in the New England Journal
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of Medicine and 1 of 179 original
articles in Clinical Chemistry.
Three articles were classified as A, 2
as AB, 1 as AC, and 1 as B.
An outcome study addresses
the question of whether use of
the studied intervention (in this
case a laboratory test) leads to an
anticipated outcome (1, 2 ). The
randomized controlled trial is a
powerful design strategy for such
studies, avoiding many pitfalls that
occur with other study designs
(2 ). Three of the outcome studies
identified in this pilot study used a
randomized controlled trial de-
sign that involved some variant of
a test-treat-counsel policy to be
compared with a policy not involv-
ing the testing element.
Before-and-after diagnostic
assessment of clinical impact is an-
other appropriate design for evalu-
ating clinical outcomes of the use
of laboratory tests (3 ), as elegantly
demonstrated in the study by
Stramer et al. (Table 1). This study
investigated the effect of prospec-
tive screening of all blood donors
for West Nile virus, and the results
indicated that carriers of the virus
were eliminated from the US Red
Cross blood supplies, and no infec-
tions were detected among recipi-
ents after the introduction of this
screening program.
We identified good examples
of diagnostic biochemical outcome
studies, but the absolute number of
these studies was disappointingly
low, indicating insufficient docu-
mentation of the health outcomes
produced by diagnostic biochemi-
cal analyses. This insufficiency is
probably attributable to multifac-
eted causes. An important aspect is
undoubtedly the complexity and
high costs of outcome studies
(1, 4 ), because many steps lie be-
tween test findings and outcome.
Research is needed that addresses
Table 1. Diagnostic biochemical outcome studies.a
Study report Study design Biochemical test Outcomeb
Smith AD et al. Use of exhaled nitric
oxide measurements to guide
treatment in chronic asthma. N Engl
J Med 2005;352:2163–73.
Randomized controlled trial
(N  97), 12-month
follow-up
Exhaled nitric oxide Frequency of exacerbations of
asthma and mean daily
dose of inhaled
corticosteroid (AB)
Crowther CA et al. Effect of treatment
of gestational diabetes mellitus on
pregnancy outcomes. N Engl J Med
2005;352:2477–86.
Randomized controlled trial
(N  1000)
Blood glucose Perinatal complications and
maternal health-related
quality of life (AB)
Tsao MS et al. Erlotinib in lung
cancer: molecular and clinical
predictors of outcomes. N Engl
J Med 2005;353:133–44.
Randomized controlled trial
(N  731)
Expression and number of
copies of epidermal
growth factor receptor
Responsiveness to Erlotinib
(A)
Stramer SL et al. West Nile Virus
among blood donors in the United
States, 2003 and 2004. N Engl J
Med 2005;353:451–9.
Prospective screening of all
blood donors for West
Nile virus; before-after
West Nile Virus RNA Elimination of carriers of the
virus from the US Red
Cross blood supplies and
no infections amongst
recipients in 2003 and
2004 (A)
Busch MP et al. Screening the blood
supply for West Nile virus RNA by
nucleic acid amplification testing. N
Engl J Med 2005;353:460–7.
Mass testing of donor
blood by amplification
testing of minipools and
individual donations
West Nile Virus RNA In high-prevalence regions
individual testing is
worthwhile (cost-effective)
due to detecting low-level
viremic donors preventing
infection amongst
recipients (AC)
Malone FD et al. First-trimester or
second-trimester screening, or both,
for Down syndrome. N Engl J Med
2005;353:2001–11.
Prospective cohort
(N  38 167)
Several biochemical
screening strategies
Capability of different
strategies for screening in
prenatal detection of Down
syndrome (A)
Petersen JR et al. Association of
transcutaneous bilirubin testing in
hospital with decreased readmission
rate for hyperbilirubinemia. Clin
Chem 2005;51:540–4.
Retrospective before-after
(N  8974)
Transcutaneous bilirubin
testing
Readmission rate (B)
a Study reports published during 2005 in Clinical Chemistry, Clinical Chemistry and Laboratory Medicine, Lancet, and New England Journal of Medicine.
b Outcomes classified as direct clinical outcome, i.e. mortality or morbidity (A); other clinical outcome, e.g., length of hospital stay, readmission rate, or satisfaction
with care (B); and/or economy-related outcome (C).
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methodological issues concerning
design and conduct of test-out-
come studies. Comprehensive dis-
cussions of this complex and im-
portant area are available (1–4),
and in the textbook Evidence-Based
LaboratoryMedicine the chapter on
assessment of outcomes is espe-
cially relevant (5 ).
Our purpose is to highlight the
importance of moving from diag-
nostic accuracy studies to evalua-
tions of the effects of test results on
clinical decision-making and sub-
sequent health outcomes. In agree-
ment with other investigators (1–
5), we support efforts to increasing
the use of outcome studies to en-
hance the effectiveness of health-
care policy and decision-making.
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Electrospray Ionization Mass
Spectrometric Analysis of the
Globin Chains in Hemoglobin
Heterozygotes Can Detect the
Variants HbC, D, and E
To the Editor:
We would like to point out that 2
recent articles in this journal about
human hemoglobin (Hb) analysis
(1, 2 ) give the false impression that
variant globin chains with 6 Da
mass difference from normal can-
not be detected in heterozygotes by
electrospray ionization mass spec-
trometry (ESI-MS). Kleinert et al.
(1 ) state: “Two important draw-
backs of the MS methods should
be mentioned. First, its insuffi-
cient resolution prevents the de-
tection of Hb mutations with small
mass differences of the globin
chains. The precision of normal
low-resolution mass measurements
was insufficient to distinguish the
wild-type -chain from several
-chain variants such as HbC, D,
or E”. Brennan (2 ) comments
similarly by stating that whereas
traditional methods readily detect
the majority of common variants,
such as HbC, HbD, or HbE, “the
substitutions involved in these, and
similar charge variants (Glu7Lys,
Glu7Gln, Asp7Asn, and Lys7
Gln) involve mass changes of 1 Da
or less, and are not detectable by
mass spectrometry.” Kleinert et al.
(1 ) also state: “Second, MS as de-
scribed here is only a qualitative
technique, and in particular, mi-
nor Hb fractions such as HbA1c
or HbA2, which are important for
diagnosis of diabetes mellitus or
thalassemias, respectively, cannot
be quantified.”
While we agree that ESI-MS
cannot detect the zero mass
change mutations (Lys7Gln and
Leu3 Ile), we maintain it is not
necessary to resolve the variant and
normal globin chains in heterozy-
gotes to detect variants that differ
in mass from normal by 1 Da
(Glu7Lys, Glu7Gln, Asp7Asn,
Asn3 Ile). In 2003, Rai et al. (3 )
showed that variants differing by
1 Da from normal can be detected
if present at 10% abundance. In
that report, the normal -chain
mass was determined with a preci-
sion of 0.05 Da SD, which resulted
in a 0.10 Da mass change being de-
tectable with 95% confidence. We
routinely analyze Hb on a quadru-
pole instrument and, owing to im-
proved performance since 2003,
generally achieve 0.03 Da SD on
the normal-chain when using the
-chain for internal calibration.
For example, 50 normal blood
samples analyzed over the last 4
months gave a mean -chain mass
of 15 867.255 Da (0.026 Da SD).
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